Notably, a 2020 clinical trial involving patients with nonalcoholic steatohepatitis (NASH) revealed a 15% incidence of tumors (benign, malignant, or unspecified) (35/239) among those administered semaglutide, compared to 8% (6/80) in the control group [108]
Except youre wondering Have I been lied to? or Am I broken? Because despite starting your own GLP-1 journey, semaglutide just isnt getting the scale moving like you had hoped
True GLP-2 (Glucagon-Like Peptide-2) is a distinctly different endogenous sequence utilized primarily in intestinal epithelial research, not metabolic lipolysis models
If you have other complications you experience, be sure to communicate those to your plastic surgeon during your consultation
Retatrutide is expected to follow a similar pattern
Ambetter from Fidelis Care has the cheapest health insurance in NYC